Pharmaceutical Technology

JULY 14, 2025

An injectable version of lenacapavir given twice a year was approved by the US Food and Drug Administration (FDA) last month, licensed as a pre-exposure prophylaxis (PrEP) option for HIV prevention. How will RFK Jr’s American dream for vaccines play out? Sign up for our daily news round-up!

Vaccines 52

Vaccines Packaging Hospitals Communication 52

The Checkup by Singlecare

JANUARY 18, 2024

in 2027 and other countries in 2025, when a generic version may be approved. Drug and Food Administration (FDA). intrauterine device of brand-name Skyla See latest prices Heather (norethindrone) $46 per 1 package of 28, 0.35 mg tablets $5 per 1 package of 28, 0.35 mg tablets $5 per 1 package of 28, 0.35

Insurance 52

Insurance Insurance Coverage Packaging Pharmaceutical Companies 52

European Pharmaceutical Review

FEBRUARY 22, 2023

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. The payload is packaged inside a dissolvable needle, loaded within a microsyringe that is attached to a folded, self-inflating balloon. the enteric coating and the capsule dissolve.

Immunization 105

Immunization Packaging Labelling FDA 105

Pharmacy Times

JULY 7, 2025

Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Takeda has informed the FDA that the manufacturing of Gammagard S/D will cease in December 2027.

FDA 97

FDA Immunization Compounding Pharmacies Hospitals 97

Pharmaceutical Technology

JULY 1, 2025

The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Don’t let policy changes catch you off guard.

FDA 52

FDA Packaging Communication Hospitals 52

Pharmaceutical Technology

JULY 2, 2025

The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027. How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication FDA Hospitals 52

Pharmaceutical Technology

JULY 2, 2025

With the additional funds from Sanofi’s investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. How will RFK Jr’s American dream for vaccines play out? As of December 2024, the company reported cash reserves of $85.2m.

Packaging 52

Packaging Communication Hospitals Insurance 52